The conference will open with a keynote from Marcus and Amber Capone, founders of Veterans Exploring Treatment Solutions, whose personal search for relief from PTSD helped bring psychedelic treatment into the national spotlight. Their session sets the stage for a broader discussion on the complexities of integrating these therapies into standard practice. Following their presentation, Matthew Zorn, Deputy General Counsel at the U.S. Department of Health and Human Services, will provide a federal policy update, specifically addressing the regulatory landscape and safety standards currently under review.

While interest in psychedelics among clinicians has nearly doubled over the past decade, knowledge gaps remain a significant concern. Research indicates that while over 80% of psychiatrists view these compounds as promising, only a fraction of providers demonstrate objective knowledge regarding their clinical application. The program addresses this by hosting a panel of experts, including Charles Raison, Andrew Penn, Rakesh Jain, and Saundra Jain, to examine the rigorous demands of patient selection, staffing, and clinical monitoring.

Beyond the immediate sessions, HMP Global intends to solidify its role in this transition by announcing plans for a dedicated 2027 meeting on psychedelics and a forthcoming peer-reviewed journal. By focusing on independent, evidence-based discourse, the event seeks to prepare the medical community for a period of change where patient advocacy and scientific discovery increasingly intersect.